Old cells repair damage in the brains of multiple sclerosis patients

Medical Xpress | January 23, 2019

A new study shows that there is a very limited regeneration of cells in the brains of patients diagnosed with multiple sclerosis (MS). These findings underline the importance of treating MS at an early stage of disease progression when the affected cells can repair the damage, as they are not replaced by new ones. The results are published in the journal Nature by researchers from Karolinska Institutet and Uppsala University in Sweden. Nerve cells in the brain communicate with one another through nerve fibers that form complex networks. Many nerve fibers are insulated by a casing of myelin, which contributes to the high-speed transmission of nerve impulses. Myelin is not formed by the nerve cells but by another type of cell called oligodendrocytes. MS is a disease caused by the body's immune system attacking the myelin and oligodendrocytes. This leads to deteriorated transmission of signals in the nerve fibers and can entail nerve cell death, a combination that causes serious neurological impairments and in severe cases the patient's death.

Spotlight

Labs are facing increasing pressure to be more efficient, more cost-effective and get drugs to market faster. Combine this with a desire by consumers to align themselves with ‘green’ and eco-friendly suppliers, and it’s no surprise many pharmaceutical companies and university labs are choosing to make their labs sustainable.

Spotlight

Labs are facing increasing pressure to be more efficient, more cost-effective and get drugs to market faster. Combine this with a desire by consumers to align themselves with ‘green’ and eco-friendly suppliers, and it’s no surprise many pharmaceutical companies and university labs are choosing to make their labs sustainable.

Related News

MEDICAL

Hillstream BioPharma to Announce Collaborating with Sapien Biosciences

Hillstream | June 30, 2022

Hillstream BioPharma, Inc., a U.S.-based biotechnology company developing novel therapeutic candidates targeting ferroptosis for cancer treatment, announced a collaboration with an Indian pioneer biobank and peonalized medicine company that leverages Saarum Innovation's global life sciences research expertise, Sapien Biosciences. The collaboration is aimed at assessing the compatibility of HSB-1216 with immune checkpoint inhibitors. HSB-1216, Hillstream’s most advanced candidate, is an IMCD modulator that targets various types of solid tumors. In an exhaustive study in Germany, the active drug in HSB-1216 was found to be efficacious in a clinical pilot for devastating cancers, including epithelial carcinomas and triple-negative breast cancer. Hillstream aims to build an early clinical proof-of-concept by beginning a clinical investigation with HSB-1216 in 2022. With this collaboration, Hillstream will be able to use Sapien’s patient samples and rich datasets to validate its HSB-1216 for the development of novel cancer therapeutics. We are initiating studies, in collaboration with Sapien Biosciences, to determine the synergy between HSB-1216, our ferroptosis inducer and nivolumab, an anti-PD1 antibody.” He stated, “In addition, we will also study the potential synergistic effects of HSB-1216 with the recently approved Bristol Myers Squibb drug Opdualag® (nivolumab + relatlimab), a fixed dose combination of an anti-PD1 MAb + anti-LAG3 MAb, to demonstrate that targeting a ferroptosis-associated metabolism in tumors may improve the efficacy of cancer immunotherapy.” Randy Milby, Hillstream’s Chief Executive Officer. We are excited to extend our collaboration with Hillstream Biopharma to evaluate potential synergy between their HSB-1216 molecule and ICIs using our expertise in establishing patient tissue-derived cell models in oncology, immunology and Immune-oncology Previously, Sapien demonstrated potent anti-cancer activity of HSB-1216 in primary triple negative breast cancer cells which were presented at AACR 2020.” Dr. Jugnu Jain, CEO, Sapien Biosciences.

Read More

MEDICAL

DxTerity Diagnostics Announces the Launch of IFN-1 Test for Lupus

DxTerity | June 13, 2022

DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus. DxTerity's test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE disease severity and prognosis. High IFN-1 levels have been shown to lead to higher likelihood of disease severity and an increased risk for the development of lupus nephritis in SLE patients. The DxTerity IFN-1 Test is the first commercial IFN-1 gene expression assay. Patients living with lupus can find it difficult to predict and interpret symptoms. Each person's experience is unique and not all patients respond to standard treatments. Disease symptoms and treatment failure may be the result of a person's specific genomic activity. The DxTerity IFN-1 Test measures the expression levels of 4 genes associated with IFN-1 activity and identifies a patient as IFN-1 high or low. This information can be used by a healthcare provider to guide treatment. Rheumatologists have long been faced with limited therapy options for lupus management. With the recent FDA approval and availability of the Type-1 Interferon receptor blocking therapy anifrolumab (Saphnelo®), lupus patients have a new and much needed treatment option. We are excited to launch the DxTerity IFN-1 Test, the first available IFN-1 gene signature test to provide information regarding a person's unique genomic activity, It is our mission to transform patient care by developing diagnostic tools that support a personalized approach to the treatment of immune-mediated disease." Bob Terbrueggen, Ph.D., Founder and CEO of DxTerity Diagnostics. About DxTerity DxTerity Diagnostics is an ISO 13485-certified genomics company with a CLIA-licensed, CAP-accredited laboratory based near Los Angeles, CA. DxTerity Diagnostics develops simple, fast, and affordable genomic tests for disease diagnosis and disease monitoring.

Read More

MEDICAL

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

biotech, biotechnology, cell, gene, tissue | June 10, 2022

SOPHiA GENETICS (Nasdaq: SOPH), the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, and the Spanish Diagnóstica Longwood today announced from the European Hematology Association Congress in Vienna that they have combined their expertise to develop a new Chronic Lymphocytic Leukemia (CLL) solution to advance CLL care. This collaboration will unify the wide variety of current guideline recommendations into one single application aiming to improve CLL characterization and CLL research practices in Iberia. SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM™ Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas. The Platform computes a wide array of genomic variants needed to continually hone machine learning algorithms designed to accurately detect rare and challenging cases. The growing number of users of the SOPHiA DDM™ community can share and access insights by pulling the relevant signals detected from the noise, ultimately saving time and helping to make better-informed decisions. The new CLL solution allows for progress of Chronic Lymphocytic Leukemia research using genomic analysis. This could lead to better detection of the disease, which accounts for 25-30% of all leukemia cases in Western countries and affects yearly more than 100,000 people globally[1], and ultimately improve patient care. Thanks to the SOPHiA DDM™ Platform and IDIBAPS, hematopathologists can now access guidelines for the mutational status of TP53, immunoglobulin (IG) gene rearrangements and their somatic hypermutation status, while benefitting from the identification of 23 CLL-specific genes for SNVs, InDels and CNVs including NOTCH1, SF3B1, ATM, IGLV3-21, BTK, PLCG2, BCL2, del13q14, and trisomy 12, all in one single NGS workflow. The new CLL solution has already been used in routine in Spain, with further opportunities throughout the country, and in Latin America through Diagnóstica Longwood's distribution channels. We are proud to work together with some of the most renowned experts in the field of Chronic Lymphocytic Leukemia research around the world. This partnership is a great example of how combining advanced data analytics with emerging CLL strategies can move the possibilities of data-driven medicine forward." Lara Hashimoto, Chief Business Officer at SOPHiA GENETICS. It is a great satisfaction to see how thanks to the partnership with SOPHiA GENETICS and Diagnóstica Longwood we will be able to transfer into clinical practice the relevant information generated for so many years in the research of CLL using a simple and robust assay." Elías Campo, principal investigator and director of IDIBAPS. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 790 hospital, laboratory, and biopharma institutions globally. About IDIBAPS The August Pi i Sunyer Biomedical Research Institute (IDIBAPS) is a biomedical research center of excellence that addresses the most common diseases in our environment. It is a public consortium comprising the Catalan Government (Generalitat de Catalunya), the Hospital Clínic Barcelona, the Faculty of Medicine and Health Sciences at the University of Barcelona and the CSIC Institute of Biomedical Research of Barcelona. About 1,500 professionals are organized in a hundred research groups. IDIBAPS undertakes translational research. It focuses on ensuring that the questions that arise at the patient's bedside have a response in the laboratory, and that advances made in the laboratory are promptly applied to patients. With over 1,200 articles published annually, it is the leading biomedical research center in Spain.

Read More